Welcome to our dedicated page for Diamedica Therapeutics SEC filings (Ticker: DMAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The DiaMedica Therapeutics Inc. (DMAC) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret complex documents. As a clinical-stage biopharmaceutical company focused on DM199 for preeclampsia, fetal growth restriction and acute ischemic stroke, DiaMedica uses SEC filings to report material clinical, regulatory, financing and governance events.
Recent Form 8-K filings illustrate how these documents inform investors about key developments. For example, DiaMedica has filed 8-Ks describing an in-person pre-IND meeting with the U.S. Food and Drug Administration for its planned U.S. Phase 2 preeclampsia study, including the FDA’s request for an additional non-clinical embryo-fetal development and pre- and postnatal development study in a rabbit model. Other 8-Ks detail private placement transactions, a Sales Agreement for an at-the-market equity offering program, and the entry into related securities purchase and registration rights agreements.
DiaMedica also uses 8-K filings to furnish quarterly financial results press releases, outline changes in executive leadership such as the appointment of a new Chief Medical Officer, and summarize separation agreements with departing officers. These filings complement the company’s periodic reports, which contain broader discussions of risk factors, clinical trial status, cash resources and operating expenses.
On Stock Titan, users can access DiaMedica’s 10-K annual reports, 10-Q quarterly reports, 8-K current reports and related exhibits as they are posted to EDGAR. AI-generated summaries highlight important sections, such as clinical development updates, capital-raising arrangements, and key contract terms, helping readers quickly understand what each filing means for DM199 and the company’s broader pipeline. Form 4 insider transaction reports, when available, can also be reviewed to see how officers and directors are transacting in DMAC shares.
DiaMedica Therapeutics Inc. is asking shareholders at its May 20, 2026 annual meeting to elect seven directors, ratify Baker Tilly US, LLP as auditor, approve executive pay on an advisory basis, and expand its 2019 Omnibus Incentive Plan.
The plan amendment would add 3,500,000 shares for equity awards, bringing the plan’s total authorization to 10,500,000 shares and extending its term by ten years. As of March 23, 2026, DiaMedica had 53,805,628 common shares outstanding and disclosed a three-year average equity award burn rate of about 5.3%.
DiaMedica Therapeutics Inc. reported full-year 2025 results showing a larger operating loss as it increased investment in its clinical pipeline while maintaining a strong cash position. Total operating expenses rose to 34,397 (in thousands) from 26,681 (in thousands), driven by higher research and development and general and administrative spending.
The company recorded a net loss of 32,766 (in thousands) for 2025 compared with 24,444 (in thousands) in 2024. As of December 31, 2025, cash and cash equivalents were 15,647 (in thousands) and marketable securities were 44,243 (in thousands), supported by 43,282 (in thousands) of net proceeds from common share issuances. Management expects this cash runway to fund operations through the second half of 2027 while advancing its DM199 programs in preeclampsia, fetal growth restriction, and acute ischemic stroke, including the ongoing ReMEDy2 Phase 2/3 trial and planned Phase 2 studies in early-onset preeclampsia.
DiaMedica Therapeutics Inc. outlines its strategy as a clinical-stage biopharmaceutical company developing DM199, a recombinant human tissue kallikrein-1, for preeclampsia, fetal growth restriction and acute ischemic stroke. DM199 has U.S. Fast Track designation for stroke and is supported by extensive Asian experience with urinary and porcine KLK1 analogs.
The company highlights interim Phase 2 preeclampsia data from South Africa showing statistically significant blood pressure reductions, improved uterine artery blood flow and no placental transfer signals. In stroke, the global Phase 2/3 ReMEDy2 trial treats patients within 24 hours of symptom onset, targeting the majority of patients who are ineligible for tPA/TNK or mechanical thrombectomy. DiaMedica also describes a broad patent estate around DM199 and DM300, long potential exclusivity, and reliance on Catalent for GMP manufacturing.
DiaMedica Therapeutics investor Leon G. Cooperman reports beneficial ownership of 3,450,000 voting common shares, representing 6.6% of the company’s outstanding shares based on 52,077,439 shares outstanding as of November 10, 2025. The stake consists of 2,450,000 shares held directly by Mr. Cooperman and 1,000,000 shares held by The Leon and Toby Cooperman Foundation, a charitable trust where he is a trustee. He reports sole voting and dispositive power over all 3,450,000 shares and certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of DiaMedica.
Dialectic Life Sciences SPV LLC, related Dialectic entities, and John Fichthorn updated their ownership report on DiaMedica Therapeutics Inc. common shares. The Dialectic entities now report beneficial ownership of 0 shares, or 0.0% of the class. Fichthorn individually reports beneficial ownership of 153,983 voting common shares, representing 0.3% of the outstanding class, with sole voting and dispositive power over this amount.
DiaMedica Therapeutics Inc. received an amended ownership report showing that Swedish investor Trill AB and its board member Jan Stahlberg beneficially own 8,825,742 common shares, representing 16.9% of the company.
All of these shares are reported with shared voting and shared dispositive power; neither Trill AB nor Stahlberg reports sole power to vote or dispose of any shares. The percentage is based on 52,077,439 DiaMedica common shares outstanding as of November 10, 2025, as disclosed in a recent quarterly report. The filing also certifies that the position is held on a passive basis, not for the purpose of changing or influencing control of DiaMedica.
DiaMedica Therapeutics Inc. director Semba Charles Pauling reported an equity-based compensation grant. On January 2, 2026, he acquired 3,355 shares of common stock at $8.42 per share, bringing his directly held stake to 47,963 shares.
The footnote explains that these shares are issuable upon settlement of restricted stock units granted under the company’s Amended and Restated 2019 Omnibus Incentive Plan, in lieu of cash retainer fees totaling $28,250. The restricted stock units are scheduled to vest in four nearly equal installments on March 31, June 30, September 30, and December 31, 2026, meaning the director earns the related shares over the course of the year as service-based conditions are met.
DiaMedica Therapeutics Inc. reported an update on its DM199 preeclampsia program following a pre-IND meeting with the U.S. Food and Drug Administration. The FDA requested one additional non-clinical 10-day modified embryo-fetal development and pre- and postnatal development study in a rabbit model before proceeding with the planned study of DM199 in preeclampsia. Preparations for this new rabbit study have begun and results are expected to be available by the second quarter of 2026.
The company reiterates forward-looking statements about the potential clinical benefits of DM199 for preeclampsia and acute ischemic stroke, and notes that outcomes depend on future non-clinical and clinical results, regulatory feedback, funding, and operational factors such as site activation and enrollment in trials.
DiaMedica Therapeutics Inc. (DMAC) director reports stock option exercise. A company director exercised a stock option to acquire 12,000 common shares of DiaMedica on 11/21/2025 at an exercise price of $2.20 per share, with the price shown after converting the original CAD$ exercise price to US$ on the transaction date. Following this transaction, the director directly owns 87,854 common shares of DiaMedica. The derivative position reported was a stock option (right to buy) for 12,000 shares that was fully vested and, after the exercise, the number of derivative securities beneficially owned is reported as 0.